Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [2210]

Study reports a novel prognostic biomarker for lung cancer

Study reports a novel prognostic biomarker for lung cancer

Novel drug combination shows promise for advanced her2-negative breast cancer

Novel drug combination shows promise for advanced her2-negative breast cancer

Novel bispecific design improves CAR T–cell immunotherapy for childhood leukaemia

Novel bispecific design improves CAR T–cell immunotherapy for childhood leukaemia

Sharing good practice ‘critical’ to improving UK lung cancer survival say experts

Sharing good practice ‘critical’ to improving UK lung cancer survival say experts

Immune networks in tumours prime responses to a personalised immunotherapy

Immune networks in tumours prime responses to a personalised immunotherapy

First MYC inhibitor to demonstrate safety and anti-tumour activity in a phase I first-in-human clinical trial

First MYC inhibitor to demonstrate safety and anti-tumour activity in a phase I first-in-human clinical trial

FDA approves erdafitinib for locally advanced or metastatic urothelial carcinoma

FDA approves erdafitinib for locally advanced or metastatic urothelial carcinoma

European Medicines Agency is looking at approving lazertinib, in combination with amivantamab, for the first-line treatment of patients with EGFR-mutated NSCLC

European Medicines Agency is looking at approving lazertinib, in combination with amivantamab, for the first-line...

FDA approves enfortumab vedotin-ejfv with pembrolizumab for locally advanced or metastatic urothelial cancer

FDA approves enfortumab vedotin-ejfv with pembrolizumab for locally advanced or metastatic urothelial cancer

FDA grants accelerated approval to pirtobrutinib for chronic lymphocytic leukaemia and small lymphocytic lymphoma

FDA grants accelerated approval to pirtobrutinib for chronic lymphocytic leukaemia and small lymphocytic lymphoma

More from ecancer